Ameriprise Financial Inc Fate Therapeutics Inc Transaction History

Ameriprise Financial Inc

$381 Billion
Q3 2024

A detailed history of Ameriprise Financial Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Ameriprise Financial Inc holds 249,742 shares of FATE stock, worth $414,571. This represents 0.0% of its overall portfolio holdings.

Number of Shares

249,742

Previous 242,432 3.02%

Holding current value

$414,571

Previous $795,000 9.94%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.12 - $5.57 $22,807 - $40,716	7,310 Added 3.02%	249,742 $874,000
Q2 2024 Aug 14, 2024	SELL	$3.26 - $7.08 $136,783 - $297,062	-41,958 Reduced 14.75%	242,432 $795,000
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $115,903 - $273,387	32,741 Added 13.01%	284,390 $2.09 Million
Q4 2023 Feb 14, 2024	SELL	$1.65 - $3.94 $39,340 - $93,941	-23,843 Reduced 8.65%	251,649 $941,000
Q3 2023 Nov 14, 2023	BUY	$2.02 - $5.04 $55,335 - $138,065	27,394 Added 11.04%	275,492 $584,000
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $814,145 - $1.13 Million	171,039 Added 221.96%	248,098 $1.18 Million
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $246,907 - $647,550	58,233 Added 309.32%	77,059 $439,000
Q4 2022 Feb 14, 2023	SELL	$9.86 - $23.83 $653,037 - $1.58 Million	-66,231 Reduced 77.87%	18,826 $189,000
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $109,050 - $186,898	5,183 Added 6.49%	85,057 $1.91 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $173,212 - $412,963	9,742 Added 13.89%	79,874 $1.98 Million
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $13.1 Million - $26.6 Million	-441,520 Reduced 86.29%	70,132 $2.72 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $13.6 Million - $18.3 Million	-285,019 Reduced 35.78%	511,652 $29.9 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $7.6 Million - $12.3 Million	128,223 Added 19.18%	796,671 $47.2 Million
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $3.14 Million - $4.32 Million	46,743 Added 7.52%	668,448 $58 Million
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $25.8 Million - $41.9 Million	357,066 Added 134.93%	621,705 $51.3 Million
Q4 2020 Feb 12, 2021	SELL	$38.09 - $100.95 $2.83 Million - $7.49 Million	-74,186 Reduced 21.9%	264,639 $24.1 Million
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $463,235 - $616,936	-15,233 Reduced 4.3%	338,825 $13.5 Million
Q2 2020 Aug 14, 2020	SELL	$20.21 - $35.23 $3.05 Million - $5.32 Million	-150,968 Reduced 29.89%	354,058 $12.1 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $25 Million - $46.1 Million	-1,445,247 Reduced 74.1%	505,026 $11.2 Million
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $5.99 Million - $9.28 Million	447,711 Added 29.8%	1,950,273 $38.2 Million
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $12.4 Million - $18 Million	799,286 Added 113.65%	1,502,562 $23.3 Million
Q2 2019 Aug 14, 2019	BUY	$15.61 - $20.44 $11 Million - $14.4 Million	703,276 New	703,276 $14.3 Million
Q2 2018 Aug 14, 2018	SELL	$9.16 - $13.48 $809,414 - $1.19 Million	-88,364 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$6.3 - $13.77 $556,693 - $1.22 Million	88,364 New	88,364 $862,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account

Ameriprise Financial Inc Fate Therapeutics Inc Transaction History